PAR-22-047: Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Closed
This grant is closed. A newer notice from the same program is open now: Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) (PAR-25-297). Status: Due dates in the notice, expires November 5, 2027. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 5, 2024.
From the official notice on Grants.gov, last changed November 15, 2021. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNIA
- Median yearly award$1.9 million
- Typical project length4.5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under PAR-22-047 were run by National Institute on Aging (NIA, 10 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-047 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-AG-28-009 | August 13, 2026 | Expected deadline June 18, 2027 | Forecast |
| PAR-25-297 | December 4, 2024 | Due dates in the notice, expires November 5, 2027 | Open |
| PAR-24-223 | June 25, 2024 | Closed December 3, 2024 | Closed |
Key dates
| Posted | November 15, 2021 |
|---|---|
| Deadline | November 5, 2024 |
| Archived by Grants.gov | December 11, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Most of the program's money (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.
Funded under PAR-22-047 so far
NIH funded 10 projects under PAR-22-047 in fiscal 2023 to 2026, at 9 institutions. The median yearly award was $1.9 million.
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-25-297, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-047 still open?
No. It closed on November 5, 2024. A newer notice is open: PAR-25-297, due dates in the notice, expires November 5, 2027.
Who can apply for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)?
Closed November 5, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-22-047?
NIH RePORTER lists 10 projects funded under PAR-22-047 in fiscal 2023 to 2026, at 9 institutions. The most were at University of California, San Diego, University of Arizona, Indiana University Indianapolis.
Who has won Aging Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, The Trustees of Columbia University in the City of New York, University of Southern California. The program made 11,026 awards worth $19 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)